Balaji Amines Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹468 Cr +37.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
BA

Balaji Amines Ltd

Q1 FY27Chemicals & Petrochemicals

Balaji Amines Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹456Cr
+27.4% YoY
+15.4% QoQ
Net profit
₹78Cr
+110.8% YoY
+20% QoQ
Margin
25%
+10 pp YoY
+1 pp QoQ

Based on Balaji Amines Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,226
Market cap₹7.0K Cr
P/E34.5

The short version

Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase. EBITDA for Q1 FY27: Rs. 121 Cr, up 91.51% YoY from Rs. 63 Cr in Q1 FY26.

From Balaji Amines Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase.
  • Total Revenue for Q1 FY27: Rs. 461 Cr (vs Rs. 367 Cr in Q1 FY26), up 25.7% year-on-year.
  • Volume Growth Outlook: FY27 volume growth guided at 10-15%, with a medium-term growth target of 20-30%.

2 more points from Balaji Amines Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • ₹1000 Cr+ expansion cycle nearing completion on consolidated basis (Page 14)
  • Capital work-in-progress of Rs. 401.06 Cr at BSCL for:
  • Greenfield expansion to manufacture HCN, NaCN, EDTA, EDTA-Na, and other advanced chemicals
  • Brownfield expansions for EDA-based chemical production (Page 28)
  • Upcoming projects:
  • HCN, Sodium Cyanide, EDTA & EDTA-2Na greenfield project, commissioning targeted by end FY27 (Page 13)
  • EDA derivatives project (DETA, TETA, PIP, AEEA & AEP), commissioning targeted during FY27 (Page 13)
  • NMM (N-Methyl Morpholine) plant expansion: 5,000 TPA proposed, expected commissioning by FY27 (Pages 14, 12)
  • Acetonitrile (ACN) expansion: 9,000 TPA proposed additional capacity, commissioning expected in FY27 (Pages 14, 12)
  • DME plant: 100,000 TPA, India's first commercial-scale, successfully commissioned in Q1 FY27 (Page 12)

2 more points from Balaji Amines Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It mentions the following relevant points: - The company has a "healthy order pipeline" supporting growth outlook (Page 5). - Improving demand across key end-user industries is cited as a factor sustaining strong performance (Page 5). - There is confidence in delivering sustainable growth backed by disciplined execution and the order pipeline (Page 5).

Balaji Amines Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Balaji Amines Ltd Q1 FY27 results — key figures

Balaji Amines Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue456358+27.4%395+15.4%
Operating profit (EBITDA)11655+110.9%94+23.4%
Operating margin25%15%+10 pp24%+1 pp
Profit before tax10649+116.3%86+23.3%
Net profit (PAT)7837+110.8%65+20%
EPS (₹)23.1311.73+97.2%19.51+18.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹468 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Balaji Amines Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Balaji Amines Ltd Q1 FY27 results?

Revenue from Operations for Q1 FY27: Rs. 456 Cr (vs Rs. 358 Cr in Q1 FY26), a 27% year-on-year increase. EBITDA for Q1 FY27: Rs. 121 Cr, up 91.51% YoY from Rs. 63 Cr in Q1 FY26.

What is Balaji Amines Ltd share price analysis?

Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.

Is Balaji Amines Ltd planning capital expenditure?

₹1000 Cr+ expansion cycle nearing completion on consolidated basis (Page 14)

Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.